DENVER — Connected care solution provider HealthSpot aims to bring rapid lab tests to retail pharmacy clinics via new technology from Samsung.

Samsung LABGEO PT10 lab test analyzer

HealthSpot said Monday that at the 2015 NACDS Total Store Expo it will showcase the Samsung LABGEO PT10 clinical chemistry analyzer, a compact, point-of-care lab device that analyzes a drop of a pharmacy patient’s blood — obtained from a finger stick — while he or she waits. Through the technology, consumers can get fast, accurate blood tests for cholesterol, diabetes and liver tests, and other lab tests and see the results in as soon as seven minutes.

Plans call for HealthSpot to deploy the Samsung device in its telehealth stations. An enclosed, 40-square-foot kiosk, the HealthSpot station uses cloud-based telemedicine software and biometric devices that allow patients to be seen and treated for basic health conditions in a virtual doctor’s visit.

The HealthSpot technology will connect lab results with the doctor’s electronic medical record as well as with the consumer’s personal health record and health insurance plan and billing.

With the addition of Samsung’s blood analyzer, pharmacy customers will be able to get affordable, on-demand lab results along with access to health care providers inside HealthSpot stations at retail pharmacy locations. HealthSpot kiosks are already deployed at select Rite Aid stores in Ohio.

“Adding labs to HealthSpot significantly enhances our mission to transform health care for consumers and providers. We are transforming retail clinics into a true extension of the local medical community and widening the scope of services that can be offered via telehealth,” stated HealthSpot chief executive officer Steve Cashman. “The addition of blood analysis via Samsung’s smart point-of-care technology will allow providers to go one step further for virtual exams inside the HealthSpot station and serve patients better than ever before.”

The Samsung LABGEO PT10 is pending approval with the Food and Drug Administration and is not yet sold in the United States, HealthSpot noted. The device is CE/IVD registered for international use and sold outside the U.S.

With the addition of point-of-care technology to the telehealth stations, clinicians will be able to get on-demand results to make decisions right at the point of care, providing health systems with efficiency and cost reduction while improving health outcomes, according to HealthSpot.

“We are helping consumerize health care — no more needles, no more wait and all at a lower cost. People like that,” Cashman added.